Anti-BCL2 [bcl-2/100] mAb

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-BCL2 [bcl-2/100] mAb
• Research fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
• Clone: bcl-2/100
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Human
• Host: Mouse
• Application: IHC ; WB
• Description: Monoclonal antibody directed against both isoforms of BCL-2 protein.
• Immunogen: Synthetic peptide of amino acids 41-54 of human bcl-2 oncoprotein
• Immunogen uniprot id: P10415
• Isotype: IgG1
• Myeloma used: P3/NS1/1-Ag4.1

Target Details

• Target: Bcl2
• Target background: The pro-survival protein BCL2 derives its name from B-cell lymphoma 2, as it is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. There are two isoforms, alpha and beta, of Bcl-2 have been identified and are a result of alternative splicing at the C-terminus. BCL-2 protein is involved in apoptosis, and inhibits the function of pro-apoptotic proteins such as Bax and Bak. Damage to the Bcl-2 gene has been identified as a cause of a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukaemia, and lung cancer, and a possible cause of schizophrenia and autoimmunity. It is also a cause of resistance to cancer treatments. This antibody recognises both the alpha and beta isoforms of BCL-2.

Applications

• Application: IHC ; WB

Handling

• Format: Liquid
• Concentration: 8 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
• Shipping conditions: Dry ice

References

• Hirpara et al. 2020. Redox Biol. 30:101403. PMID: 31954371.
• Steinbach et al. 2020. PLoS One. 15(1):e0227676. PMID: 31935257.
• Jeffery et al. 2017. Clin Exp Immunol. 188(3):394-411. PMID: 28176332.
• Soilu-Hänninen et al. 1999. J Neurosci. 19(12):4828-38. PMID: 10366617.
• Navratil et al. 1995. J Clin Pathol. 48(1):18-21. PMID: 7706514.
• Ashton-Key et al. 1995. Histopathology. 26(1):75-8. PMID: 7713486.
• Piris et al. 1994. Br J Cancer. 69(2):337-41. PMID: 8297731.
• Leek et al. 1994. Br J Cancer. 69(1):135-9. PMID: 8286195.
• de Jong et al. 1994. Cancer Res. 54(1):256-60. PMID: 8261449.
• Pezzella et al. 1993. N Engl J Med. 329(10):690-4. PMID: 8393963.
• Doussis et al. 1993. Am J Clin Pathol. 99(6):663-7. PMID: 8322700.
• Pezzella et al. 1993. Histopathology. 22(1):39-44. PMID: 8436340.
• Gaulard et al. 1992. Am J Pathol. 140(5):1089-95. PMID: 1374590.
• Pezzella et al. 1992. Br J Cancer. 65(1):87-9. PMID: 1733447.
• Pezzella et al. 1990. Lancet. 336(8729):1510-1. PMID: 1979117.